No sell transactions available for this period
Regeneron Pharmaceuticals, Inc. filed its 13F report for Q2 2026 on August 07, 2026. The portfolio totaled 177.22 M reflecting a +270.10% change from the prior quarter, spanning 3 assets. The top 10 holdings comprised 100.0% of the portfolio, with Financials as the largest sector allocation. Quarterly activity included 1 new positions and 0 complete exits.
Items:
Total Value:
| Issuer Name | Class | Value | Shares | Option Type |
|---|
Regeneron Pharmaceuticals submitted their Form 13F-HR for the Q2 2026 period on 08/07/2026. This was the only submission for the quarter.
In the Q2 2026 filing, Regeneron Pharmaceuticals reported a managed portfolio value of 177.22 M, consisting of 3 individual positions.
This page displays the raw filing documents. To see which stocks Regeneron Pharmaceuticals bought or sold during Q2 2026, please visit Regeneron Pharmaceuticals's Portfolio Analysis page.